What must be excluded in patients with anaplastic large cell lymphoma (ALCL) prior to initiation of treatment?

Updated: May 08, 2020
  • Author: Delong Liu, MD, PhD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print


It is imperative to rule out systemic involvement in patients with skin disease as management and prognosis is completely different. In addition, every effort should be made to distinguish primary cutaneous anaplastic large cell lymphoma (ALCL) from lymphomatoid papulosis (LyP). LyP is a benign disease with prolonged relapsing and remitting clinical course. However, patients with LyP are at increased risk of various kinds of cutaneous or systemic lymphomas, including ALCL. The presence of ALK gene rearrangement in patients with systemic disease provides both predictive and prognostic information.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!